Oppenheimer assumes ViroPharma (VPHM) at Outperform with a $35 price target citing an improved...

|By:, SA News Editor

Oppenheimer assumes ViroPharma (VPHM) at Outperform with a $35 price target citing an improved outlook for H2 2013-2014 characterized by "continued Cinryze growth (lapping the comps on Vancocin) and continued news flow from the pipeline." Analyst Akiva Felt also calls Maribavir development a "call option with near-term catalyst potential.” (Previous: VPHM spikes on buyout chatter)